Given that several FASN inhibitors are currently undergoing clinical evaluation, future research should also explore the therapeutic potential of combination regimens involving FASN inhibitors with Hedgehog or FLT3 inhibitors in FLT3-ITD-mutated AML [27,28]. The gene discussed is FLT3; the disease is acute myeloid leukemia.